Predictive value of preoperative routine examination for the prognosis of patients with pT2N0M0 or pT3N0M0 colorectal cancer

Table 1 Clinical characteristics of the colorectal cancer patients

Variables	DFS	Non-DFS	P value
n	451	62
Male, (%)	61.20	62.90	0.890
Age, yr	66.65 ± 11.08	68.48 ± 10.87	0.221
Diabetes mellitus (%)	10.86	12.90	0.666
Hypertension (%)	31.49	30.65	1.000
Smoking history1 (%)	20.40	30.65	0.072
Alcohol intake history2 (%)	11.87	20.97	0.068
Family history of CRC (%)	4.88	4.84	1.000
NAFLD (%)	21.51	29.03	0.195
BMI, kg/m2	23.33 ± 3.22	23.59 ± 2.55	0.538

¹Smoking history was defined in our study as regular daily inhalation of cigarettes that lasted at least until surgery without cessation.

²Alcohol consumption was defined as an average daily intake of ethanol greater than or equal to 30 grams per day (about two drinks a day) without abstinence.

CRC: Colorectal cancer; NAFLD: Non-alcoholic fatty liver disease; BMI: Body mass index; DFS: Disease-free survival.

Table 2 Univariate Cox regression analysis of disease-free survival

Variables	BE	SE	Wald	P value	HR (95%CI)
Male, (%)	0.179	0.276	0.420	0.517	1.196 (0.696-2.055)
Age, yr	-.005	0.012	0.169	0.681	0.995 (0.972-1.018)
BMI, kg/m2	0.026	0.041	0.413	0.520	1.027 (0.947-1.113)
Diabetes mellitus (%)	-0.284	0.468	0.369	0.544	0.753 (0.301-1.883)
Hypertension (%)	-0.133	0.257	0.269	0.604	0.875 (0.529-1.447)
Smoking history (%)	0.610	0.280	4.751	0.029	1.840 (1.063-3.185)
Alcohol intake history (%)	0.590	0.324	3.315	0.069	1.805 (0.956-3.407)
Family history of CRC (%)	0.435	0.518	0.705	0.401	1.545 (0.560-4.266)
NAFLD (%)	0.393	0.288	1.857	0.173	1.482 (0.842-2.608)
WBC, 109/L	-0.027	0.077	0.122	0.727	0.974 (0.837-1.132)
LY, 109/L	0.035	0.210	0.028	0.868	1.036 (0.686-1.564)
MO, 109/L	-0.164	0.841	0.038	0.846	0.849 (0.163-4.413)
NEUT, 109/L	-0.037	0.090	0.167	0.683	0.964 (0.808-1.150)
Hb, g/L	0.005	0.006	0.727	0.394	1.005 (0.993-1.017)
PLT, 109/L	-0.005	0.002	5.957	0.015	0.995 (0.991-0.999)
T-BIL, μmol/L	0.006	0.025	0.066	0.798	1.007 (0.958-1.058)
D-BIL, μmol/L	-0.010	0.086	0.013	0.908	0.990 (0.836-1.172)
TP, g/L	0.002	0.021	0.012	0.913	1.002 (0.961-1.045)
ALB, g/L	-0.014	0.030	0.216	0.642	0.986 (0.931-1.045)
GLB, g/L	0.018	0.029	0.389	0.533	1.018 (0.962-1.078)
ALT, U/L	-0.002	0.008	0.036	0.849	0.998 (0.983-1.015)
AST, U/L	-0.016	0.019	0.637	0.425	0.985 (0.948-1.023)
TBA, μmol/L	0.000	0.023	0.000	0.990	1.000 (0.956-1.047)
PA, mg/L	0.002	0.002	0.857	0.355	1.002 (0.998-1.006)
UREA, mmol/L	-0.001	0.088	0.000	0.990	0.999 (0.841-1.186)
FBG, mmol/L	0.119	0.072	2.742	0.098	1.126 (0.978-1.297)
Cr, μmol/L	0.002	0.008	0.072	0.789	1.002 (0.986-1.019)
UA, mmol/L	-0.392	1.119	0.123	0.726	0.675 (0.075-6.055)
HbA1c, %	0.017	0.156	0.011	0.915	1.017 (0.749-1.380)
CEA, ng/mL	0.004	0.004	1.067	0.302	1.004 (0.996-1.013)
CA19-9, U/mL	0.000	0.001	0.071	0.789	1.000 (0.998-1.001)
TC, mmol/L	0.144	0.179	0.648	0.421	1.155 (0.813-1.639)
TG, mmol/L	0.216	0.232	0.868	0.351	1.241 (0.788-1.955)
HDL-C, mmol/L	-0.054	0.501	0.012	0.914	0.948 (0.355-2.529)
LDL-C, mmol/L	0.142	0.223	0.405	0.525	1.152 (0.744-1.784)
Apo-A1, g/L	-0.788	0.803	0.964	0.326	0.455 (0.094-2.194)
Apo-B, g/L	0.707	1.075	0.432	0.511	2.027 (0.246-16.676)
LP-a, mg/dL	-0.001	0.012	0.005	0.944	0.999 (0.977-1.022)

CRC: Colorectal cancer; NAFLD: Nonalcoholic fatty liver disease; BMI: Body mass index; WBC: White blood cell; LY: Lymphocyte; MO: Monocyte; NEUT: Neutrophil; Hb: Hemoglobin; PLT: Blood platelet count; T-BIL: Total bilirubin; D-BIL: Direct bilirubin; TP: Total protein; ALB: Albumin; GLB: Globulin; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; TBA: Total bile acid; PA: Prealbumin; UREA: Urea nitrogen; FBG: Fasting blood glucose; Cr: Creatinine; UA: Uric acid; HbA1c: Glycosylated hemoglobin A1c; CEA: Carcinoembryonic antigen; CA19-9: Carbohydrate antigen 19-9; TC: Total cholesterol; TG: Triglyceride; HDL-C: High-density lipoprotein cholesterol; LDL-C: Low density lipoprotein cholesterol; Apo-A1: Apolipoprotein A1; Apo-B: Apolipoprotein B; LP-a: Lipoprotein A; HR: Hazard ratio; CI: Confidence interval.

Table 3 Univariate Cox regression analysis of overall survival

Variables	BE	SE	Wald	P value	HR (95%CI)
Male, (%)	-0.329	0.313	1.102	0.294	0.720 (0.390-1.330)
Age, yr	0.031	0.015	4.211	0.040	1.031 (1.001-1.062)
BMI, kg/m2	0.020	0.049	0.157	0.692	1.020 (0.926-1.123)
Diabetes mellitus (%)	0.098	0.477	0.042	0.838	1.102 (0.433-2.809)
Hypertension (%)	0.014	0.222	0.004	0.949	1.014 (0.656-1.568)
Smoking history (%)	0.418	0.343	1.482	0.223	1.519 (0.775-2.976)
Alcohol intake history (%)	0.492	0.394	1.558	0.212	1.635 (0.755-3.541)
Family history of CRC (%)	0.476	0.600	0.630	0.427	1.610 (0.497-5.215)
NAFLD (%)	0.614	0.329	3.471	0.062	1.847 (0.969-3.523)
WBC, 109/L	-0.054	0.094	0.327	0.568	0.948 (0.789-1.139)
LY, 109/L	0.074	0.249	0.089	0.765	1.077 (0.662-1.754)
MO, 109/L	-1.432	1.110	1.663	0.197	0.239 (0.027-2.105)
NEUT, 109/L	-0.074	0.112	0.434	0.510	0.929 (0.746-1.156)
Hb, g/L	-0.003	0.007	0.149	0.700	0.997 (0.984-1.011)
PLT, 109/L	-0.002	0.002	1.072	0.301	0.998 (0.993-1.002)
T-BIL, μmol/L	-0.070	0.038	3.484	0.062	0.932 (0.866-1.004)
D-BIL, μmol/L	-0.243	0.128	3.611	0.057	0.784 (0.610-1.008)
TP, g/L	-0.005	0.025	0.040	0.841	0.995 (0.946-1.046)
ALB, g/L	-0.056	0.034	2.643	0.104	0.946 (0.885-1.011)
GLB, g/L	0.045	0.033	1.788	0.181	1.046 (0.979-1.116)
ALT, U/L	-0.001	0.009	0.009	0.925	0.999 (0.981-1.017)
AST, U/L	-0.004	0.016	0.052	0.819	0.996 (0.966-1.028)
TBA, μmol/L	-0.009	0.031	0.089	0.765	0.991 (0.932-1.053)
PA, mg/L	0.000	0.003	0.001	0.978	1.000 (0.995-1.005)
UREA, mmol/L	0.022	0.104	0.045	0.832	1.022 (0.834-1.252)
FBG, mmol/L	0.122	0.082	2.242	0.134	1.130 (0.963-1.326)
Cr, μmol/L	-0.011	0.010	1.260	0.262	0.989 (0.969-1.009)
UA, mmol/L	-2.209	1.874	1.390	0.238	0.110 (0.003-4.321)
HbA1c, %	0.206	0.086	5.754	0.016	1.229 (1.038-1.455)
CEA, ng/mL	0.008	0.004	4.896	0.027	1.008 (1.001-1.016)
CA19-9, U/mL	-0.005	0.007	0.476	0.490	0.995 (0.981-1.009)
TC, mmol/L	0.431	0.206	4.350	0.037	1.538 (1.026-2.305)
TG, mmol/L	0.211	0.272	0.601	0.438	1.235 (0.724-2.107)
HDL-C, mmol/L	0.264	0.552	0.229	0.632	1.303 (0.441-3.846)
LDL-C, mmol/L	0.434	0.258	2.820	0.093	1.543 (0.930-2.559)
Apo-A1, g/L	0.848	0.832	1.038	0.308	2.335 (0.457-11.931)
Apo-B, g/L	1.200	1.216	0.974	0.324	3.320 (0.306-35.966)
LP-a, mg/dL	0.006	0.011	0.253	0.615	1.006 (0.983-1.029)

CRC: Colorectal cancer; NAFLD: Nonalcoholic fatty liver disease; BMI: Body mass index; WBC: White blood cell; LY: Lymphocyte; MO: Monocyte; NEUT: Neutrophil; Hb: Hemoglobin; PLT: Blood platelet count; T-BIL: Total bilirubin; D-BIL: Direct bilirubin; TP: Total protein; ALB: Albumin; GLB: Globulin; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; TBA: Total bile acid; PA: Prealbumin; UREA: Urea nitrogen; FBG: Fasting blood glucose; Cr: Creatinine; UA: Uric acid; HbA1c: Glycosylated hemoglobin A1c; CEA: Carcinoembryonic antigen; CA19-9: Carbohydrate antigen 19-9; TC: Total cholesterol; TG: Triglyceride; HDL-C: High-density lipoprotein cholesterol; LDL-C: Low density lipoprotein cholesterol; Apo-A1: Apolipoprotein A1; Apo-B: Apolipoprotein B; LP-a: Lipoprotein A; HR: Hazard ratio; CI: Confidence interval.

Table 4 Multivariate Cox regression analysis of overall survival

Variables	BE	SE	Wald	P value	HR (95%CI)
CEA, ng/mL	0.019	0.005	16.075	< 0.001	1.019 (1.010-1.029)
TC, mmol/L	0.006	0.011	0.253	0.615	1.006 (0.983-1.029)

CEA: Carcinoembryonic antigen; TC: Total cholesterol; TG: Triglyceride; HR: Hazard ratio; CI: Confidence interval.